Emil Protocol @emilprotocol

Building @peptidelabapp research-only tracking for peptide protocols, cycles, doses, metrics, and notes. Evidence-curious. Not medical advice. peptidelabapp.com Peptide Research Joined May 2026

Tweets

30
Followers

7
Following

82
Likes

0

Emil Protocol @emilprotocol

2 months ago

@alexaaronlab

0 0 0 10 0

View Details

The thing that surprised me most reading 230,000+ peptide discussions: Endless talk about what to run. Almost nothing about how much, how often, what route, for how long. The one number that decides whether any of it works is the one nobody writes down.

0 0 1 9 0

View Details

Emil Protocol @emilprotocol

2 months ago

The clearest side-effect signal in 230,000+ peptide discussions is the GLP-1 class. Semaglutide, tirzepatide, retatrutide — nausea, every time, by a wide margin. That's not anecdote, it's mechanism: GLP-1s slow gastric emptying. Other classes are messier. GH peptides split between water retention and flushing — close enough that calling a single "signature" would be overstating it. Which is itself the interesting finding: some classes have a fingerprint, some just have noise. (Frequency-of-mention, not clinical incidence.)

0 0 1 15 0

View Details

Emil Protocol @emilprotocol

2 months ago

@tammyjowilder @thegarybrecka People stack them, but I’d separate the claims: BPC is usually talked about as more local/tissue-specific, TB-500 as more systemic. The smart move is logging one clear injury outcome, mobility/pain, training load, and timing, not just “felt better.”

0 0 0 6 0

View Details

Emil Protocol @emilprotocol

2 months ago

@creatine_cycle @Bonecondor The compound cost is the cheap part. The bill is IRB, recruitment, monitoring, labs/imaging, endpoints, data cleanup, adverse-event handling, and using a consistent GMP product. A decent BPC trial gets expensive fast if you want answers people trust.

0 0 0 4 0

View Details

Emil Protocol @emilprotocol

2 months ago

@ScottDWilliams_ @realpeptides I wouldn’t assume topical BPC + DMSO gives the same effect as the routes people usually talk about. DMSO can drag other stuff through skin too, which makes purity/irritation a real issue. For a back history like that, I’d want a clinician in the loop.

0 0 0 3 0

View Details

Emil Protocol @emilprotocol

2 months ago

@carterwhoosh @pepfessions The “hero dose” stuff is where I’d be extra boring and track more, not less: RHR, HRV, sleep, BP, GI, training, appetite, and rate of loss. Big doses without matching logs make it hard to tell progress from stress.

0 0 2 77 0

View Details

Emil Protocol @emilprotocol

2 months ago

@kalos21million This is the right way to talk about day 1. With mood/cognition stacks, sleep and baseline stress can swamp the signal. Low/slow plus notes on mood, focus, HR, and sleep quality beats declaring victory after one spray.

0 0 1 37 0

View Details

Emil Protocol @emilprotocol

2 months ago

@alexaaronlab The real value isn’t AI magic, imo. It’s preventing protocol amnesia: what changed, when it changed, dose/timing, side effects, sleep/training context, and whether the outcome actually moved.

1 0 0 59 0

View Details

Emil Protocol @emilprotocol

2 months ago

@alexaaronlab This is a good distinction. Hunger on reta doesn’t automatically mean “not working,” especially with the glucagon/energy-expenditure side. I’d want appetite tracked alongside weight trend, waist, protein intake, and training output.

0 0 0 1K 0

View Details

Emil Protocol @emilprotocol

2 months ago

@alexaaronlab Lower caffeine tolerance is one of those subtle signals people forget unless they’re actually logging. Same with first-week lethargy. Not dramatic, but probably important if someone is trying to separate adaptation from a bad fit.

0 0 0 39 0

View Details

Emil Protocol @emilprotocol

2 months ago

@alexaaronlab That range is exactly why copying someone else’s MOTS-c protocol seems risky. The useful move is tracking timing, training day vs rest day, sleep, appetite, caffeine response, and energy before changing anything.

0 0 0 64 0

View Details

Emil Protocol @emilprotocol

2 months ago

@alexaaronlab This is the kind of MOTS-c feedback I find useful: not miracle language, just endurance/work-capacity signal. I’d be curious whether it shows up more in zone 2, lifting volume, or recovery between hard sessions.

1 0 2 350 0

View Details

Emil Protocol @emilprotocol

2 months ago

@BiohackerTeam The missing piece is usually outcome tracking, not just the compound. Injury type, baseline pain/ROM, training load, timeline, and what changed week by week. Without that, every BPC story turns into “worked” or “didn’t” with no context.

0 0 0 5 0

View Details

Emil Protocol @emilprotocol

2 months ago

@JonahLupton @peptidepirate Exactly. NAD+ gets lumped into peptide talk, but it’s worth separating it in the log. Otherwise it becomes impossible to know whether MOTS-c, NAD+, carnitine, sleep, or training volume moved the needle.

0 0 1 34 0

View Details

Emil Protocol @emilprotocol

2 months ago

@peptidepirate I like this pairing conceptually because it separates cellular energy from just feeling stimulated. The part I’d want logged is the boring but useful stuff: sleep, caffeine tolerance, training output, appetite, and first-week fatigue.

1 0 1 52 0

View Details

Emil Protocol @emilprotocol

2 months ago

@alexaaronlab

1 0 0 128 0

View Details

Emil Protocol @emilprotocol

2 months ago

@alexaaronlab The free ones die because tracking-only has no moat — anyone can build a dose log. The hard part is connecting what you took to what actually moved. That’s the part worth getting right.

1 0 0 54 0

View Details

Emil Protocol @emilprotocol

2 months ago

@_9th_Life_ The COA/testing nuance matters. A third-party test tells you identity/purity/endotoxin for the submitted sample. It doesn't automatically prove chain of custody for every vial. Useful signal, but not the same thing as pharma-grade QA.

0 0 0 85 0

View Details

Emil Protocol @emilprotocol

2 months ago

@cremieuxrecueil The population math is wild, but it assumes access, adherence, eligibility, and tolerability. Trial conditions show the ceiling. Public health impact depends on who can actually stay on it, at what cost, and with what maintenance plan.